---
title: "Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291806404.md"
description: "Fate Therapeutics (NASDAQ: FATE) will present preliminary clinical data for its off-the-shelf CAR T-cell product candidate FT819, targeting systemic sclerosis, at the ISSCR 2026 Annual Meeting in Montréal from July 8-11, 2026. The presentation highlights initial findings on this iPSC-derived immunotherapy aimed at autoimmune diseases."
datetime: "2026-07-06T12:31:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291806404.md)
  - [en](https://longbridge.com/en/news/291806404.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291806404.md)
---

# Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

On July 6, 2026, Fate Therapeutics, Inc. shared that they will present initial clinical findings on their off-the-shelf CAR T-cell product, FT819, at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting in Montréal, Canada from July 8 to 11, 2026. Fate Therapeutics is a clinical-stage biopharmaceutical corporation listed on the NASDAQ as FATE. The company focuses on delivering a revolutionary array of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to cancer and autoimmune disease patients. This event will showcase important updates on their product aimed at benefiting a large patient population.

### Related Stocks

- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)

## Related News & Research

- [Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages](https://longbridge.com/en/news/293837447.md)
- [Fate Therapeutics reports preliminary FT819 CAR-T data showing skin score improvement in systemic sclerosis patients](https://longbridge.com/en/news/291803727.md)
- [Linde's Q2 2026 Earnings: What to Expect](https://longbridge.com/en/news/293494879.md)
- [Tempest Therapeutics partners with Senlang Biotech to advance TPST-4003 in vivo CAR-T into first-in-human trial](https://longbridge.com/en/news/293330940.md)
- [5 Best ETFs for the Rest of 2026](https://longbridge.com/en/news/293484852.md)